Brian Piper is Chief Financial Officer of Sana Biotechnology.

Prior to joining Sana, Mr. Piper served as Chief Financial Officer of Scorpion Therapeutics until its acquisition by Eli Lilly in 2025, and thereafter was Chief Financial Officer of Antares Therapeutics, following its spin-off from Scorpion. Previously, he was Chief Financial Officer of Prelude Therapeutics, where he helped lead the company through its initial public offering in 2020 and a subsequent underwritten follow-on offering in early 2021. Earlier, Mr. Piper served as Chief Financial Officer of Aevi Genomic Medicine (formerly Medgenics) and as Vice President of Finance and Investor Relations. He also spent 13 years at Shire Pharmaceuticals, holding senior roles across investor relations, corporate venture capital, and other finance functions. Mr. Piper began his career at Celera Genomics and Otsuka Pharmaceuticals, Inc.

Brian obtained his M.B.A. from the University of Maryland and his B.B.A. from the University of Notre Dame.